Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) Target Price at $11.05

Shares of enGene Holdings Inc. (NASDAQ:ENGN) have received an average recommendation of “Hold” from the fourteen analysts that are currently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokers that have covered the stock in the last year is $11.0455.

ENGN has been the topic of a number of research analyst reports. Citizens Jmp restated a “market perform” rating on shares of enGene in a report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (e+)” rating on shares of enGene in a report on Wednesday, August 12th. HC Wainwright reiterated a “buy” rating and issued a $4.00 price objective on shares of enGene in a research report on Tuesday, September 8th. Morgan Stanley lowered enGene from an “equal weight” rating to an “underweight” rating and set a $3.00 price objective on the stock. in a research report on Thursday, June 18th. Finally, Wall Street Zen raised enGene from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC raised its holdings in enGene by 179.8% in the 4th quarter. Perceptive Advisors LLC now owns 5,869,076 shares of the company’s stock worth $52,998,000 after purchasing an additional 3,771,840 shares in the last quarter. Siren L.L.C. boosted its stake in shares of enGene by 57.5% during the 1st quarter. Siren L.L.C. now owns 5,253,159 shares of the company’s stock valued at $35,774,000 after purchasing an additional 1,916,895 shares in the last quarter. Cormorant Asset Management LP boosted its stake in shares of enGene by 72.1% during the 4th quarter. Cormorant Asset Management LP now owns 4,000,000 shares of the company’s stock valued at $36,120,000 after purchasing an additional 1,676,405 shares in the last quarter. Blue Owl Capital Holdings LP increased its position in shares of enGene by 2.5% during the fourth quarter. Blue Owl Capital Holdings LP now owns 3,360,937 shares of the company’s stock valued at $30,349,000 after buying an additional 82,831 shares during the period. Finally, Eventide Asset Management LLC purchased a new position in shares of enGene during the fourth quarter valued at about $8,578,000. 64.16% of the stock is owned by hedge funds and other institutional investors.

enGene Price Performance

Shares of enGene stock opened at $1.91 on Thursday. The company’s fifty day simple moving average is $1.83 and its two-hundred day simple moving average is $3.64. enGene has a 12-month low of $1.40 and a 12-month high of $12.25. The firm has a market cap of $127.95 million, a PE ratio of -1.69 and a beta of -0.28. The company has a quick ratio of 10.21, a current ratio of 10.21 and a debt-to-equity ratio of 0.11.

enGene (NASDAQ:ENGN) last issued its quarterly earnings data on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.04). As a group, equities analysts expect that enGene will post -1.81 EPS for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.